OrbiMed’s Intersect ENT, Inc XENT Stock Holding History

OrbiMed’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-68,553	Closed	-$812K	–	165
2020 Q1	$812K	Buy	+68,553	New	+$1.52M	0.01%	137

Other funds holding XENT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OrbiMed's XENT Position: Q2 2020 in Review

OrbiMed sold out of Intersect ENT, Inc (XENT) in Q2 2020, closing a stake of 68,553 shares — an estimated $812K sold.

OrbiMed first reported a position in XENT in Q1 2020 and held it in 1 quarter. The position peaked at $812K in Q1 2020. 108 funds tracked by Wall St. Rank hold XENT as of Q2 2020.

OrbiMed reported no remaining Intersect ENT, Inc position as of Q2 2020 after selling out during the quarter.
OrbiMed sold 68,553 Intersect ENT, Inc shares in Q2 2020, an estimated $812K.
OrbiMed first reported a position in Intersect ENT, Inc in Q1 2020 and held it in 1 quarter.
OrbiMed's Intersect ENT, Inc position peaked at $812K in Q1 2020.
108 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2020.

Based on OrbiMed's 13F filing for Q2 2020, filed 14 Aug 2020.